Cargando…
Refining the Characterization and Outcome of Pathological Complete Responders after Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Lessons from the Randomized Phase III VESPER (GETUG-AFU V05) Trial
SIMPLE SUMMARY: On the basis of a deep analysis of data collected in a randomized trial of perioperative chemotherapy in muscle-invasive bladder cancer, we refined the characterization and outcome of patients whose cystectomy specimens were pathologically free of cancer (pCR) after neoadjuvant chemo...
Autores principales: | Culine, Stéphane, Harter, Valentin, Krucker, Clémentine, Gravis, Gwenaelle, Fléchon, Aude, Chevreau, Christine, Mahammedi, Hakim, Laguerre, Brigitte, Guillot, Aline, Joly, Florence, Fontugne, Jacqueline, Allory, Yves, Pfister, Christian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10046214/ https://www.ncbi.nlm.nih.gov/pubmed/36980628 http://dx.doi.org/10.3390/cancers15061742 |
Ejemplares similares
-
Design of a randomized controlled phase III study of dose dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as peri-operative chemotherapy for patients with locally advanced transitional cell cancer of the bladder. The French GETUG/AFU V05 VESPER trial
por: Pfister, Christian, et al.
Publicado: (2020) -
Invited commentary on GETUG-AFU 16
por: Lee, W. Robert
Publicado: (2016) -
Differential SINE evolution in vesper and non-vesper bats
por: Ray, David A, et al.
Publicado: (2015) -
Misal diario y vesperal /
Publicado: (1946) -
Misal diario y vesperal /
por: Lefebvre, Gaspar, 1880-1966
Publicado: (1946)